THE DEAL, AT A GLANCE
2/4 reviewedOne Biosciences
One Biosciences
One Biosciences makes single-cell tumor maps and clinician-ready reports from preserved or frozen tissue samples.
One Biosciences raised Series A, announced 2026-09-1101What it doesOne Biosciences makes single-cell tumor maps and clinician-ready reports from preserved or frozen tissue samples.Source-grounded · automated review · Explore ↗
02Who is involvedBacked by Galion, France 2030From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03What happenedOne Biosciences raised Series A, announced 2026-09-11From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗04Why it mattersIts service aims to make detailed single-cell cancer data usable in real clinical studies.Interpretation · Explore ↗
Click a part to explore its evidence. The image is supplied by the cited source.Original record source ↗
One Biosciences · Financing Record
Explore source-linked visual explanations for One Biosciences. Unsupported claims are withheld while source review continues.
Record 12158 · Recorded date: 2026-09-11
Explore company records →